Print

Search Results: Prevention, Detection & Risk + Pancreatic Cancer (8 results)

Pancreatic Cancer Early Detection for People at High Risk

https://www.facingourrisk.org/research-clinical-trials/study/227/pancreatic-cancer-early-detection-for-people-at-high-risk

Prevention
Registry and biobank for high risk people undergoing pancreatic cancer screening

The study will collect clinical information, family history, and samples (blood, saliva or cheek swab) from people and families at risk for pancreatic cancer. Collecting this information and samples will create a resource to drive research necessary for early detection and prevention of pancreatic ductal adenocarcinoma (PDAC).


Testing a Vaccine for Cancer Prevention in People with a BRCA1 or BRCA2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/172/testing-a-vaccine-for-cancer-prevention-in-people-with-a-brca1-or-brca2-mutation

Prevention
People with a BRCA1 or BRCA2 mutation

This study will look at a new vaccine known as INO-5401 used alone or combined with a second vaccine called INO-9012. The study will test if the vaccine is safe (without large side effects) and test a new way of giving vaccines. It will also test whether the vaccine activates the immune system. A goal of this research is to reduce cancer risk in people with a BRCA1 or BRCA2 mutation. Additional studies will be needed to learn if this vaccine approach lowers cancer risk in mutation carriers. 


Pancreatic Cancer Screening Study (CAPS5)

https://www.facingourrisk.org/research-clinical-trials/study/222/pancreatic-cancer-screening-studycaps5

Prevention
Screening study for people at high risk for pancreatic cancer

CAPS5 is a study looking at screening for early cancer in people with an elevated lifetime risk of developing pancreatic cancer. The goal is to study biomarkers derived from images and tissue samples (blood, pancreas fluid, duodenal fluid) for the early detection of pancreatic cancer and precancerous lesions.

 


Blood Markers of Early Pancreas Cancer

https://www.facingourrisk.org/research-clinical-trials/study/141/blood-markers-of-early-pancreas-cancer

Prevention
Observational study for people with family history of pancreas cancer or an inherited mutation linked to pancreatic cancer risk.

The purpose of this study is to try to find markers of early pancreatic cancer for individuals at higher-than-average risk, expedite the diagnosis in individuals with symptoms, and substantially improve an individual's chance of surviving the disease.


IGNITE-TX - Identifying Individuals for Genetic Testing for Familial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/266/helping-people-with-a-genetic-mutation-in-brca1-brca2-or-lynch-syndrome-talk-to-their-family-members-about-their-risk-for-cancer-and-find-the-best-way-to-get-family-members-tested

Prevention
People with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome who have relatives who have not been tested

The IGNITE-TX study is all about helping people with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome talk to their family members about their risk for cancer and find the best way to get family members tested.


Preliminary Evaluation of Screening for Pancreatic Cancer in Patients with an Inherited Genetic Risk Due to a BRCA1, BRCA2, PALB2 or ATM Mutation

https://www.facingourrisk.org/research-clinical-trials/study/121/screening-for-pancreatic-cancer-in-patients-with-an-inherited-brca1-brca2-palb2-or-atm-mutation

Prevention

Improved screening for pancreatic cancer in high-risk groups, such as people with an inherited BRCA1, BRCA2, ATM, or PALB2 mutation, may help find cancer early and improve survival rates. People enrolled in this study will undergo screening using endoscopic ultrasound or MRI of the abdomen.


A Pancreatic Cancer Screening Study for High Risk Individuals

https://www.facingourrisk.org/research-clinical-trials/study/95/pancreatic-cancer-screening-study-for-high-risk-people

Prevention

The purpose of this study is to screen and detect pancreatic cancer and precancer in people with either a strong family history of pancreatic cancer, or an inherited mutation associated with pancreatic cancer risk.

Magnetic Resonance Imaging (MRI) will be used to screen for early stage pancreatic cancer. Participants will also be asked to donate a blood sample at specific intervals for the creation of a blood bank necessary for the development of a blood-based screening test for pancreatic cancer. 


Pancreatic Cancer Early Detection Program

https://www.facingourrisk.org/research-clinical-trials/study/20/pancreatic-cancer-early-detection

Prevention

This is a study looking at esophageal ultrasound and Magnetic Resonance Imaging (MRI) as a screening for pancreatic cancer in high risk individuals. 


Additional Results on Clinicaltrials.gov Prevention, Detection & Risk + Pancreatic Cancer
10 results

A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals
NCT ID: NCT03250078 (https://classic.clinicaltrials.gov/show/NCT03250078)

Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk
NCT ID: NCT02478892 (https://classic.clinicaltrials.gov/show/NCT02478892)

A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus
NCT ID: NCT03937453 (https://classic.clinicaltrials.gov/show/NCT03937453)

Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
NCT ID: NCT06122896 (https://classic.clinicaltrials.gov/show/NCT06122896)

Anamorelin Study for Advanced Pancreatic Cancer
NCT ID: NCT04844970 (https://classic.clinicaltrials.gov/show/NCT04844970)

Blood Markers of Early Pancreas Cancer
NCT ID: NCT03568630 (https://classic.clinicaltrials.gov/show/NCT03568630)

A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
NCT ID: NCT06151223 (https://classic.clinicaltrials.gov/show/NCT06151223)

New Onset Diabetes Management for Earlier Detection of Pancreatic Cancer (NODMED)
NCT ID: NCT05188586 (https://classic.clinicaltrials.gov/show/NCT05188586)

Pancreatic Cancer Early Detection Program
NCT ID: NCT02206360 (https://classic.clinicaltrials.gov/show/NCT02206360)

DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)
NCT ID: NCT04825834 (https://classic.clinicaltrials.gov/show/NCT04825834)


About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.